Bellicum Pharmacueticals Inc. (BLCM) Trading Down 4.2%
Bellicum Pharmacueticals Inc. (NASDAQ:BLCM)’s share price traded down 4.2% during mid-day trading on Tuesday . The stock traded as low as $13.32 and last traded at $13.47, with a volume of 95,330 shares traded. The stock had previously closed at $14.06.
Several equities analysts have recently issued reports on the stock. Zacks Investment Research raised shares of Bellicum Pharmacueticals from a “sell” rating to a “hold” rating in a research note on Monday, July 11th. Piper Jaffray Cos. reiterated a “buy” rating on shares of Bellicum Pharmacueticals in a report on Saturday, July 9th. Finally, SunTrust Banks Inc. initiated coverage on shares of Bellicum Pharmacueticals in a report on Thursday, June 2nd. They issued a “buy” rating and a $20.00 target price for the company. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Bellicum Pharmacueticals presently has an average rating of “Buy” and a consensus price target of $28.00.
The company has a 50 day moving average of $13.09 and a 200-day moving average of $11.26. The company’s market capitalization is $359.02 million.
Bellicum Pharmacueticals (NASDAQ:BLCM) last issued its quarterly earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.51) by $0.07. On average, equities analysts anticipate that Bellicum Pharmacueticals Inc. will post ($2.22) EPS for the current year.
In related news, CTO Kevin M. Slawin sold 55,000 shares of the company’s stock in a transaction dated Friday, April 22nd. The shares were sold at an average price of $11.43, for a total transaction of $628,650.00. Following the transaction, the chief technology officer now owns 159,206 shares in the company, valued at approximately $1,819,724.58. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, COO Annemarie Moseley sold 25,000 shares of the company’s stock in a transaction dated Thursday, June 2nd. The stock was sold at an average price of $13.00, for a total transaction of $325,000.00. Following the transaction, the chief operating officer now owns 18,486 shares in the company, valued at approximately $240,318. The disclosure for this sale can be found here.
A hedge fund recently raised its stake in Bellicum Pharmacueticals stock. Morgan Stanley increased its stake in Bellicum Pharmacueticals Inc. (NASDAQ:BLCM) by 21.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 426,861 shares of the biopharmaceutical company’s stock after buying an additional 74,454 shares during the period. Morgan Stanley owned approximately 1.61% of Bellicum Pharmacueticals worth $8,653,000 as of its most recent filing with the SEC.
Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company is using its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system in real time.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.